Tuesday, June 08, 2010 7:00:28 AM
Delcath Systems, Inc. (DCTH) is a medical technology company specializing in cancer treatment, with its initial focus on the treatment of primary and metastatic liver cancers. DCTH recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and results were very positive.
Please see this exclusive video of Eric Whitman, MD., a highly regarded surgical oncologist who specializes in melanoma and is Director of the Atlantic Melanoma Center. Dr. Whitman attended the American Society of Clinical Oncology’s Annual Meeting, where he took special note of a presentation on Delcath’s PHP study. Dr. Whitman stresses that PHP has proven to be clinically effective.
The PHP System treatment developed by DCTH has caused the survival rate to triple for cancer patients with melanoma that has spread to their liver. The exact numbers shown are 398 days vs. 124 with the best alternative care.
There were significant factors we think were overlooked or misunderstood in Monday's market action, including:
The fact that the survival rate tripled for cancer patients treated with PHP (Percutaneous Hepatic Perfusion).
The latest data was even better than the initial press release from April. The hepatic PFS (primary endpoint) was 245 days in the PHP arm and 49 days in the BAC (best alternative care) arm.
The estimate for peak annual U.S. sales is $745 million if the PHP System is approved by the FDA for the treatment of patients with Melanoma that has spread to the liver. Sales could potentially increase to $5.6 billion if this treatment is used in primary liver cancer as well as metastases from other types of cancer.
There is just huge potential for Delcath’s PHP system. Also, there is the possibility for large “off-label” use. And if expectations play out accordingly, then the possibility for Delcath’s PHP system to be used for many other cancer treatments in the future also holds great potential.
*In addition to this article from Alpha,let me ask this question.How many shares were naked shorted Monday?My bet is a hell of alot.This crap has to end SEC.Get off the porn sights and do your jobs.
Recent DCTH News
- Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/20/2024 08:01:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/18/2024 09:10:58 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/18/2024 09:07:27 PM
- Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups • Business Wire • 09/16/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 12:00:53 PM
- Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients • Business Wire • 08/28/2024 08:01:00 PM
- Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 08/28/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 12:33:53 PM
- Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients • Business Wire • 08/27/2024 12:30:00 PM
- Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors • Business Wire • 08/26/2024 08:01:00 PM
- Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress • Business Wire • 08/20/2024 12:30:00 PM
- Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/12/2024 08:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/06/2024 04:15:07 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:36:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:12:28 PM
- Delcath Systems Reports Second Quarter 2024 Results and Business Highlights • Business Wire • 08/05/2024 08:01:00 PM
- Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™ • Business Wire • 08/05/2024 12:30:00 PM
- Delcath Systems to Participate in Upcoming Investor Conferences • Business Wire • 07/30/2024 08:01:00 PM
- Delcath Systems to Host Second Quarter 2024 Earnings Call • Business Wire • 07/22/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:06:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/09/2024 03:13:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 01:01:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:06:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 08:32:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 08:31:38 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM